Noah Berkowitz - 30 Sep 2026 Form 4 Insider Report for IOVANCE BIOTHERAPEUTICS, INC. (IOVA)

Reporting relationship: Chief Medical Officer
Issuer ticker: IOVA
Reported as of: 30 Sep 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 02 Oct 2026, 17:01:05 UTC
Prior SEC filing: 13 May 2026
Source filing: View source filing
Reporting owner signature: /s/ Noah Berkowitz

Key filing fact

Noah Berkowitz filed Form 4 for IOVANCE BIOTHERAPEUTICS, INC. (IOVA) on 02 Oct 2026.

Key facts

This page summarizes Noah Berkowitz's Form 4 filing for IOVANCE BIOTHERAPEUTICS, INC. (IOVA).
3 reported transactions and 3 derivative rows are listed below.
Accepted by SEC: 02 Oct 2026, 17:01.

Change

Previous filing in this sequence was filed on 13 May 2026.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001369900 Primary reporting owner

Berkowitz Noah

Relationship: Chief Medical Officer
Address: C/O IOVANCE BIOTHERAPEUTICS, INC., 300 ROUSE BLVD., PHILADELPHIA
Signature: /s/ Noah Berkowitz
Signature date: 02 Oct 2026

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

IOVA transaction Derivative

Stock Options (Right to Buy)

Award

Transaction value
Shares: +135,000
Change %
Price: $0.000000^*
Shares after: 135,000
Date: 30 Sep 2026
Ownership: Direct
Underlying class: Common stock
Underlying amount: 135,000
Exercise price: $14.82
Footnotes: F1

IOVA transaction Derivative

Restricted Stock Units

Award

Transaction value
Shares: +180,000
Change %
Price: $0.000000^*
Shares after: 180,000
Date: 30 Sep 2026
Ownership: Direct
Underlying class: Common stock
Underlying amount: 180,000
Exercise price
Footnotes: F1, F2

IOVA transaction Derivative

Performance Stock Units

Award

Transaction value
Shares: +135,000
Change %
Price: $0.000000^*
Shares after: 135,000
Date: 30 Sep 2026
Ownership: Direct
Underlying class: Common stock
Underlying amount: 135,000
Exercise price
Footnotes: F3, F4, F5

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 5 footnotes

Footnote F1

Provided the Reporting Person is still employed with the Issuer on the following dates, the restricted stock units ("RSUs") and options are each exercisable as follows: (i) RSUs and options for the purchase of one-third of such shares shall vest on the one-year anniversary of the date of grant; and (ii) the remaining RSUs and options shall vest in eight equal quarterly installments over the next two years, commencing with the first quarter following the first anniversary of the date of grant.

Footnote F2

Each RSU represents a contingent right to receive one share of the Issuer's common stock.

Footnote F3

Each performance stock unit ("PSU") converts into one share of the Issuer's common stock.

Footnote F4

Up to 135,000 shares of the Issuer's common stock underlying the PSUs may be earned subject to achievement of certain regulatory milestones.

Footnote F5

Such earned PSUs shall vest on the date that the Issuer publicly discloses on a Form 8-K with the U.S. Securities and Exchange Commission its receipt of certain regulatory milestones.